Review warns of growing prenatal cannabis use despite mounting evidence of risks

More pregnant individuals are using cannabis in the context of changing policy, despite recent studies showing perinatal and neurodevelopmental risks, and healthcare providers often fail to discuss the topic with patients.

Bespalova, Nadejda et al.·Current psychiatry reports·2024·Moderate Evidencenarrative review
RTHC-05136Narrative reviewModerate Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
narrative review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Recent studies show possible perinatal and longitudinal neurodevelopment risks from prenatal cannabis exposure. Healthcare providers are reluctant to discuss cannabis with pregnant patients for various reasons. Increased access through legalization may increase adverse effects.

Key Numbers

Cannabis use during pregnancy is increasing in the context of liberalized policy. Healthcare providers cite multiple reasons for reluctance to discuss cannabis with pregnant patients.

How They Did This

Narrative review of recent evidence on prenatal cannabis effects, covering perinatal outcomes, neurodevelopmental risks, and healthcare provider communication barriers.

Why This Research Matters

The gap between increasing prenatal cannabis use and incomplete clinician communication about risks means many pregnant individuals are making decisions without adequate information about potential consequences.

The Bigger Picture

The review highlights a systemic failure: even as evidence of prenatal cannabis risks accumulates, the medical system has not adequately translated this evidence into routine clinical conversations, leaving pregnant individuals to rely on non-medical information sources.

What This Study Doesn't Tell Us

Brief narrative review without systematic methodology. Does not quantify specific risk magnitudes. Healthcare provider perspectives not directly measured.

Questions This Raises

  • ?What specific barriers prevent clinicians from discussing cannabis with pregnant patients?
  • ?Would standardized screening and counseling protocols improve prenatal cannabis conversations?

Trust & Context

Key Stat:
HCPs reluctant to discuss cannabis in pregnancy
Evidence Grade:
Brief narrative review provides an overview of current concerns but without systematic evidence synthesis.
Study Age:
2024 review of recent prenatal cannabis evidence
Original Title:
Cannabis and Pregnancy.
Published In:
Current psychiatry reports, 26(11), 643-649 (2024)
Database ID:
RTHC-05136

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Why are more pregnant people using cannabis?

Changing cannabis laws, increased availability, growing social acceptance, and some women using it to manage pregnancy symptoms like nausea, despite evidence of potential risks.

Why don't doctors discuss cannabis with pregnant patients?

Healthcare providers cite various barriers including discomfort with the topic, uncertainty about the evidence, concern about stigmatizing patients, and limited training on cannabis counseling.

Read More on RethinkTHC

Cite This Study

RTHC-05136·https://rethinkthc.com/research/RTHC-05136

APA

Bespalova, Nadejda; Bunt, Gregory; Hill, Kevin P. (2024). Cannabis and Pregnancy.. Current psychiatry reports, 26(11), 643-649. https://doi.org/10.1007/s11920-024-01536-x

MLA

Bespalova, Nadejda, et al. "Cannabis and Pregnancy.." Current psychiatry reports, 2024. https://doi.org/10.1007/s11920-024-01536-x

RethinkTHC

RethinkTHC Research Database. "Cannabis and Pregnancy." RTHC-05136. Retrieved from https://rethinkthc.com/research/bespalova-2024-cannabis-and-pregnancy

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.